Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer

Trial Details

NCT ID

NCT06369259

Phase

PHASE2

Sponsor

M.D. Anderson Cancer Center

Status

RECRUITING

Cancer Type

Colorectal Cancer

Interventions

• Defactinib
• Cetuximab
• Avutometinib

Locations (sample)

• Houston, Texas, United States|29.76328,-95.36327

Key Eligibility Criteria

• Provision of signed Informed Consent prior to any screening procedures being performed.
• Non-English speaking participants will be eligible for participation with involvement of the MD Anderson Language Assistance department in the info…
• Individuals lacking the ability, based on reasonable medical judgment, to understand and appreciate the nature and consequences of participation in…
• Age ≥ 18 years at the time of informed consent.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.